Physician profile
Floyd Jones
NPI 1467481861
$1,138.02
in general payments reported to CMS, 2019-2025
20 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.55 · 2020: $33.73 · 2021: $54.63 · 2022: $29.34 · 2023: $329 · 2024: $191 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $188.93 | 2023 | Gimoti |
| Amgen INC. | $157.93 | 2022-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $149.99 | 2025 | Rexulti |
| Lexicon Pharmaceuticals, INC. | $113.85 | 2023-2024 | Inpefa |
| Inspire Medical Systems, INC. | $98.00 | 2025 | Inspire |
| Lilly USA, LLC | $58.24 | 2025 | Jardiance, Mounjaro |
| Pfizer INC. | $57.56 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $51.82 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.49 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $36.29 | 2024-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $32.26 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $25.57 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $23.97 | 2023 | Keveyis |
| Axsome Therapeutics, INC. | $16.81 | 2025 | Auvelity |
| Lundbeck LLC | $16.64 | 2023 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.61 | 2024 | |
| Abbvie INC. | $15.87 | 2025 | |
| Ardelyx, INC. | $14.26 | 2025 | Ibsrela |
| Novo Nordisk INC | $12.96 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Floyd Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.